Development of 11C-Tucatinib as a potential HER2-targeting PET radiotracer

被引：0
|
作者：
Muller, Marius [1 ]
Battisti, Umberto [1 ]
Shalgunov, Vladimir [1 ]
Jorgensen, Jesper [1 ]
Hvass, Lars [1 ]
Kramer, Vasko [2 ]
Kjaer, Andreas [1 ]
Herth, Matthias [1 ]
机构：
[1] Univ Copenhagen, Copenhagen, Denmark
[2] Positronpharma SA, Santiago, Chile
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2022年 / 108卷
关键词：
BREAST-CANCER; TRASTUZUMAB; METASTASES; ONCOGENE;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P-287
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [21] Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer
    Ko, Bong-Kook
    Lee, Sook-Yeon
    Lee, Young-Ha
    Hwang, In-Sik
    Persson, Helena
    Rockberg, Johan
    Borrebaeck, Carl
    Park, Dongeun
    Kim, Kyu-Tae
    Uhlen, Mathias
    Lee, Jong-Seo
    MOLECULAR ONCOLOGY, 2015, 9 (02): : 398 - 408
  • [22] Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors
    McDermott, Martina
    Ivers, Laura
    O'Donovan, Norma
    Crown, John
    Roninson, Igor
    Broude, Eugenia V.
    CANCER RESEARCH, 2015, 75
  • [23] Biomarkers to predict sensitivity to HER2-targeting treatment in HER2-positive advanced gastric cancer.
    Kim, Tae Yong
    Ock, Chan-Young
    Oh, Do-Youn
    Lee, Kyung-Hun
    Han, Sae-Won
    Im, Seock-Ah
    Kim, Tae-You
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Radiosynthesis of [11C]Lu 29-024:: A potential radiotracer for 5HT2 receptors PET studies
    Amokhtari, M
    Andersen, K
    Ibazizene, M
    Dhilly, M
    Dauphin, F
    Barre, L
    NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (06) : 517 - 522
  • [25] Development of an ACE2-Targeting Radiotracer for PET Imaging of the SARS-CoV-2 Entry Receptor
    Mueller, C.
    Beyer, D.
    Wang, J.
    Vaccarin, C.
    He, Y.
    Mu, L.
    Bode, J. W.
    Schibli, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S224 - S224
  • [26] Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).
    Verheijden, Gijs
    Beusker, Patrick
    Ubink, Ruud
    van der Lee, Miranda
    Groothuis, Patrick
    Goedings, Peter J.
    Egging, David
    Mattaar, Ellen
    Timmers, Macro
    Dokter, Wim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
    Brack, Simon
    Attinger-Toller, Isabella
    Schade, Babette
    Mourlane, Frederic
    Klupsch, Kristina
    Woods, Richard
    Hachemi, Helen
    von der Bey, Ulrike
    Koenig-Friedrich, Susann
    Bertschinger, Julian
    Grabulovski, Dragan
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (08) : 2030 - 2039
  • [28] Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery
    Shipunova, Victoria O.
    Kolesnikova, Olga A.
    Kotelnikova, Polina A.
    Soloviev, Vladislav D.
    Popov, Anton A.
    Proshkina, Galina M.
    Nikitin, Maxim P.
    Deyev, Sergey M.
    ACS OMEGA, 2021, 6 (24): : 16000 - 16008
  • [29] Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins
    Pioquinto-avila, Elizeth
    Gonzalez-Cruz, Aldo O.
    Solis-estrada, Jorge
    Hernandez-Juarez, Javier
    Balderas-Renteria, Isaias
    Villa-Cedillo, Sheila adela
    Perez-Trujillo, JOSe J. U. A. N.
    Arredondo-Espinoza, Eder
    ANTICANCER RESEARCH, 2024, 44 (06) : 2567 - 2575
  • [30] Targeting and imaging of HER2 overexpression tumor with a new peptide-based 68Ga-PET radiotracer
    Ardakani, Javad Biabani
    Akhlaghi, Mehdi
    Nikkholgh, Babak
    Hosseinimehr, Seyed Jalal
    BIOORGANIC CHEMISTRY, 2021, 106
12345